Tue, Nov 16|
Type 2 Diabetes: What's the scientific evidence for the role of the gut microbiome? Presented by Dr. Orville Kolterman and Jennifer McManus, RD, LDN, CDCES Sponsored by: Pendulum Therapeutics
Time & Location
Nov 16, 2021, 6:30 PM
About the event
An expanding body of evidence demonstrates that pathophysiologic changes occur in the gut microbiome of people with type 2 diabetes. These changes, along with potential management modalities, including the use of novel probiotics, will be discussed. Presenters include a renowned endocrinologist and a registered dietitian nutritionist, certified diabetes care and education specialist well versed in this science. Sufficient time will be allotted for Q and A.Presenters:
Orville Kolterman, MD
Today Orville Kolterman serves as the chief medical officer of Pendulum Therapeutics. He has been involved in diabetes care for nearly 50 years. He received his MD from University of Chicago and did his endocrinology training at Stanford School of Medicine. Dr. Kolterman is an internationally respected diabetes expert and has successfully brought four glucose-lowering pharmaceuticals from research trials to market. He also served as chief medical officer of Amylin Pharmaceuticals.
Jennifer McManus, RD, LDN, CDCES
Jennifer McManus is one of the registered dietitians at Pendulum Therapeutics. She works remote from her home in Orlando, FL. Prior to her role at Pendulum, she was a registered dietitian at AdventHealth Orlando. She is passionate about helping people manage diabetes by providing education and counseling sessions. She completed her Bachelors of Science degree at Florida State University and went on to complete her dietetic internship at Vanderbilt University Medical Center. Jen currently serves as the historian and National Nutrition Month chair for the Central Florida Academy of Nutrition and Dietetics.
Credits: 1 CEU Approved
1. Detail the pathophysiologic changes that occur in the gut microbiome of people with type 2 diabetes, including the role of butyrate, a short chain fatty acid, in the glucagon-like peptide 1 (GLP-1) physiologic pathway.
2. Delineate the beneficial functions of the gut bacteria that may be missing in the gut microbiomes of people with type 2 diabetes.
3. Detail the science and evidence for the use of a medical probiotic formulated to improve gut health and glycemic management in people with type 2 diabetes.